Q-omics provides the consensus-scored OR51T1 profile across patient tissues and cancer cell-line models. OR51T1 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, OR51T1 is differentially expressed in 2, with the highest sampling consensus in PRAD. Additionally, OR51T1 RNA expression shows 10,165 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, PRAD, and TGCT as cancer lineages where OR51T1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51T1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51T1 survival associations across molecular data types. OR51T1 RNA expression shows survival associations in the most cancer types (10), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51T1 RNA expression–survival associations across cancer types. High OR51T1 expression shows unfavorable associations in LUAD, LGG and BLCA, but favorable associations in SCLC, STAD and PRAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify SCLC as the clearest survival context for OR51T1 RNA expression.
This table summarizes OR51T1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR51T1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51T1 shows higher tumor expression in PRAD and KICH. The PRAD box plot shows higher OR51T1 RNA expression in tumor versus normal tissue (log2 FC = +0.461, t-test p < 0.001).
This table shows molecular features associated with OR51T1 in patient tissues and cancer cell lines. In patient samples, OR51T1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OR51T1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and KIDNEY.
